Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1.

George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P.

FASEB J. 2017 Apr;31(4):1398-1420. doi: 10.1096/fj.201600733R. Epub 2017 Jan 18.

PMID:
28100642
2.

Ketamine and phencyclidine: the good, the bad and the unexpected.

Lodge D, Mercier MS.

Br J Pharmacol. 2015 Sep;172(17):4254-76. doi: 10.1111/bph.13222. Epub 2015 Jul 28. Review.

3.

Emerging pharmacologic treatment options for fragile X syndrome.

Schaefer TL, Davenport MH, Erickson CA.

Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. eCollection 2015. Review.

4.

Recent insights into the mode of action of memantine and ketamine.

Johnson JW, Glasgow NG, Povysheva NV.

Curr Opin Pharmacol. 2015 Feb;20:54-63. doi: 10.1016/j.coph.2014.11.006. Epub 2014 Dec 2. Review.

5.

Inhibition of the polyamine system counteracts β-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors.

Gomes GM, Dalmolin GD, Bär J, Karpova A, Mello CF, Kreutz MR, Rubin MA.

PLoS One. 2014 Jun 12;9(6):e99184. doi: 10.1371/journal.pone.0099184. eCollection 2014.

6.

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.

Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM.

Neuropsychiatr Dis Treat. 2014 Feb 21;10:391-401. doi: 10.2147/NDT.S57909. eCollection 2014. Erratum in: Neuropsychiatr Dis Treat. 2014;10:1997.

7.

Effects of prolonged treatment with memantine in the MRL model of CNS lupus.

Marcinko K, Parsons T, Lerch JP, Sled JG, Sakic B.

Clin Exp Neuroimmunol. 2012 Sep;3(3):116-128.

8.

Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries.

Lee RH, Tseng TY, Wu CY, Chen PY, Chen MF, Kuo JS, Lee TJ.

PLoS One. 2012;7(7):e40326. doi: 10.1371/journal.pone.0040326. Epub 2012 Jul 5.

9.

The pharmacological profile of ELIC, a prokaryotic GABA-gated receptor.

Thompson AJ, Alqazzaz M, Ulens C, Lummis SC.

Neuropharmacology. 2012 Sep;63(4):761-7. doi: 10.1016/j.neuropharm.2012.05.027. Epub 2012 Jun 4.

10.

The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome.

Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X.

PLoS One. 2012;7(5):e36981. doi: 10.1371/journal.pone.0036981. Epub 2012 May 15.

11.

Cys-loop receptor channel blockers also block GLIC.

Alqazzaz M, Thompson AJ, Price KL, Breitinger HG, Lummis SC.

Biophys J. 2011 Dec 21;101(12):2912-8. doi: 10.1016/j.bpj.2011.10.055. Epub 2011 Dec 20.

12.

Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation.

Cesa LC, Higgins CA, Sando SR, Kuo DW, Levandoski MM.

Mol Pharmacol. 2012 Feb;81(2):239-49. doi: 10.1124/mol.111.076059. Epub 2011 Nov 7.

13.

Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.

Pandya A, Yakel JL.

Biochem Pharmacol. 2011 Oct 15;82(8):952-8. doi: 10.1016/j.bcp.2011.04.020. Epub 2011 May 7. Review.

14.

Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site.

Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SC.

Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95. doi: 10.1016/j.neuropharm.2010.11.003. Epub 2010 Nov 5.

15.

Pharmacodynamics of memantine: an update.

Rammes G, Danysz W, Parsons CG.

Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.

16.

Cholinergic direct inhibition of N-methyl-D aspartate receptor-mediated currents in the rat neocortex.

Flores-Hernandez J, Salgado H, De La Rosa V, Avila-Ruiz T, Torres-Ramirez O, Lopez-Lopez G, Atzori M.

Synapse. 2009 Apr;63(4):308-18. doi: 10.1002/syn.20609.

17.

Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups.

Takahashi A, Yap JJ, Bohager DZ, Faccidomo S, Clayton T, Cook JM, Miczek KA.

Psychopharmacology (Berl). 2009 May;204(1):61-71. doi: 10.1007/s00213-008-1437-8. Epub 2008 Dec 20.

18.

Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease.

Dong H, Yuede CM, Coughlan C, Lewis B, Csernansky JG.

Neuropsychopharmacology. 2008 Dec;33(13):3226-36. doi: 10.1038/npp.2008.53. Epub 2008 Apr 16.

19.

Anti-dementia drugs and hippocampal-dependent memory in rodents.

Yuede CM, Dong H, Csernansky JG.

Behav Pharmacol. 2007 Sep;18(5-6):347-63. Review.

20.

Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus.

Murray JE, Bevins RA.

Eur J Pharmacol. 2007 Apr 30;561(1-3):91-104. Epub 2007 Feb 1.

Supplemental Content

Support Center